Welcome to our dedicated page for Zimmer Biomet news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet stock.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is a global medical technology company focused on musculoskeletal health, orthopedic implants and digital and robotic technologies. This news page aggregates company announcements, press releases and market-facing updates so readers can follow how Zimmer Biomet develops and commercializes its orthopedic, trauma and digital care offerings.
Recent news highlights include earnings announcements and conference call webcasts, where Zimmer Biomet reports quarterly financial results and discusses performance across product categories such as knees, hips, sports medicine, extremities, trauma and technology and data, bone cement and surgical. The company also issues updates on its capital allocation, including quarterly cash dividends approved by its Board of Directors.
Zimmer Biomet frequently announces product and technology milestones. Examples include U.S. FDA 510(k) clearance for an enhanced version of its ROSA Knee robotic technology, FDA Breakthrough Device Designation for an iodine-treated total hip replacement system, and launches of new foot and ankle trauma solutions through its Paragon 28 business. The company also reports collaborations and integrations, such as the use of mobility intelligence technology within its mymobility care management platform, and highlights its broader connected care strategy linking robotics, digital platforms and analytics.
Investors and observers can also find updates on Zimmer Biomet’s participation in major healthcare and investor conferences, as well as news related to acquisitions like the merger with Monogram Technologies Inc. Bookmark this page to review the latest official communications from Zimmer Biomet on its orthopedic portfolio, digital and robotic technologies, financial disclosures and strategic initiatives.
Zimmer Biomet (NYSE: ZBH) appointed Jonathan M. Vigdorchik, M.D., as Chief Science, Technology and Medical Affairs Officer, effective April 14, 2026. He will report to Ivan Tornos and oversee the company's global technology portfolio, including AI, robotics, smart implants and data, plus Medical Education and the Global Advisory Board.
Dr. Vigdorchik joins from Hospital for Special Surgery, previously served as Zimmer Biomet Chief Medical Technology Advisor for Adult Reconstruction and Hip Implants, and holds academic roles including Associate Professor at Weill Cornell.
Zimmer Biomet (NYSE: ZBH) will present new clinical and operational data and showcase robotic, digital and implant innovations at the AAOS 2026 Annual Meeting on March 5-9, 2026. The company will feature products including ROSA Knee with OptimiZe, Persona IQ, Monogram TKA, Oxford Cementless Partial Knee and Z1 Femoral Hip.
Arnold Schwarzenegger will appear as the conference Presidential Guest Speaker on March 5 at 10:30 a.m. CT alongside CEO Ivan Tornos and AAOS President Ned Amendola; multiple poster and data presentations will address safety, gait metrics, readmissions and ASC efficiency.
Zimmer Biomet (NYSE: ZBH) announced a quarterly cash dividend of $0.24 per share for Q1 2026. The dividend is payable on or about April 30, 2026 to shareholders of record at the close of business on March 31, 2026.
Zimmer Biomet (NYSE: ZBH) reported Q4 2025 net sales of $2.244B (up 10.9% reported; 5.4% organic constant currency) and full-year sales of $8.232B (up 7.2% reported; 3.9% organic). GAAP diluted EPS were $0.70 Q4 and $3.55 FY; adjusted EPS were $2.42 Q4 and $8.20 FY. The company generated $1.697B operating cash flow and $1.172B free cash flow, closed three acquisitions, and announced a new $1.5B share repurchase authorization commencing Feb 9, 2026. Full-year 2026 guidance targets ~2.5%–4.5% reported revenue growth and adjusted EPS of $8.30–$8.45.
Zimmer Biomet (NYSE: ZBH) announced its fourth-quarter 2025 earnings conference call will be webcast on Tuesday, February 10, 2026 at 8:30 a.m. ET. A news release with quarterly results will be published the same day at 6:30 a.m. ET. A live audio webcast and replay will be available via the company's investor relations site: https://investor.zimmerbiomet.com. U.S. and Canada dial-in is (800) 330-6710; international callers may use +1 (213) 279-1505. Use conference ID 7090861 to join the call.
Zimmer Biomet (NYSE: ZBH) announced that members of its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 8:15 a.m. PT (11:15 a.m. ET).
A live webcast will be available on Zimmer Biomet's Investor Relations website and will be archived for replay after the conference.
Zimmer Biomet (NYSE: ZBH) announced a quarterly cash dividend of $0.24 per share for the fourth quarter of 2025. The dividend is payable on or about January 30, 2026 to stockholders of record at the close of business on December 30, 2025.
Zimmer Biomet (NYSE: ZBH) and OneStep announced an exclusive collaboration to integrate OneStep's clinically validated mobility intelligence into Zimmer Biomet's mymobility Care Management Platform for joint replacement patients, effective Dec 16, 2025.
The integration will feed smartphone-based gait and functional mobility analytics (iPhone and Android) directly into mymobility to support remote assessment, patient engagement, and clinician-tailored rehabilitation. OneStep processes more than one million gait cycles every day, providing a large real-world mobility dataset to quantify recovery trends and functional outcomes.
Zimmer Biomet (NYSE: ZBH) announced U.S. FDA 510(k) clearance of ROSA® Knee with OptimiZe™, an enhanced version of its ROSA Knee robotic system for total knee replacement surgery.
The update adds five OptimiZe features—Planning, Landmarking, Tracking, Kinematic Alignment and Experience—plus integration with ZBEdge® Analytics. The company said OptimiZe Planning™ can reduce planning time by an average of 46%. Zimmer Biomet plans a targeted release later in 2025 and expects U.S. commercial availability in Q1 2026.
Zimmer Biomet (NYSE: ZBH) said members of its management team will present at the Annual Jefferies Global Healthcare Conference in London on Tuesday, Nov. 18, 2025 at Noon GMT (7 a.m. ET). A live webcast will be available on the company's investor relations website and will be archived for replay after the conference.